38 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
from the matters discussed herein. While the Company believes in the viability of our strategy to generate sufficient revenue, control costs, and raise … Executive Officer and former Chief Strategy Officer. Mr. Kopfli alleges an improper termination for “cause” and seeks monetary damages in the amount
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
from the matters discussed herein. While the Company believes in the viability of our strategy to generate sufficient revenue, control costs, and raise … Executive Officer and former Chief Strategy Officer. Mr. Kopfli alleges an improper termination for “cause” and seeks monetary damages in the amount
10-Q
2024 Q1
EX-10.3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
Date, Executive also serves as Company’s Chief Financial and Strategy Officer, President, Treasurer and Secretary, for which positions Executive shall
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
believes in the viability of our strategy to generate sufficient revenue, control costs, and raise additional funds, when necessary, there can … a demand letter from an attorney representing Chromocell Holdings and Christian Kopfli, our former Chief Executive Officer and former Chief Strategy Officer
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
, the “Spray Formulations”).
Our Strategy
We are a clinical-stage pharmaceutical company focused on non-opioid pain blockers in the NaV space. Our … elements of our strategy to achieve our mission are:
Advance the development of CC8464 towards FDA approval for treating EM and iSFN. Based on its
424B3
dscxq369n6kgl7x64vag
16 Apr 24
Prospectus supplement
5:45pm
10-K
EX-19.1
6dn79rbv u6gx3f05jm
16 Apr 24
Annual report
4:48pm
10-K
qwxva3nf7drmy
16 Apr 24
Annual report
4:48pm
8-K
zqg52ld
18 Mar 24
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
4:05pm
8-K
EX-99.1
hzqgpsd58au1nuedl
13 Mar 24
Regulation FD Disclosure
8:00am
8-K
mh7v 0p4w
13 Mar 24
Regulation FD Disclosure
8:00am
8-K
1kb291qj 5ur
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-99.1
6uzvi
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
9h53b t6t0ws0tc28
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
way98we du
20 Feb 24
Prospectus supplement with pricing info
5:28pm
FWP
nb64pwi
12 Feb 24
Free writing prospectus
8:09am
FWP
pij32u ff
6 Feb 24
Free writing prospectus
8:43pm